Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review.
JAK inhibitors
Neutrophilic dermatosis
Pyoderma gangrenosum
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
25 May 2024
25 May 2024
Historique:
received:
19
11
2023
accepted:
26
04
2024
revised:
23
04
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
25
5
2024
Statut:
epublish
Résumé
Pyoderma gangrenosum (PG) is a rare inflammatory dermatologic condition with neutrophilic infiltration of the skin that causes pustules and ulcerations. Janus kinase (JAK) inhibitors are immunomodulating agents that have been recently described in the literature as an effective treatment for PG. We describe a patient with PG on the lower extremities successfully treated with baricitinib. We also conducted a narrative review of the literature of PG patients treated with JAK inhibitors who were refractory to other treatments.
Identifiants
pubmed: 38795155
doi: 10.1007/s00403-024-02958-6
pii: 10.1007/s00403-024-02958-6
doi:
Substances chimiques
Janus Kinase Inhibitors
0
baricitinib
ISP4442I3Y
Pyrazoles
0
Sulfonamides
0
Azetidines
0
Purines
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
238Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ashchyan HJ, Butler DC, Nelson CA et al (2018) The Association of Age with Clinical Presentation and comorbidities of Pyoderma Gangrenosum. JAMA Dermatol Apr 1(4):409–413. https://doi.org/10.1001/jamadermatol.2017.5978
doi: 10.1001/jamadermatol.2017.5978
Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol Aug 62(8):1088–1093. https://doi.org/10.1111/ijd.16676
doi: 10.1111/ijd.16676
Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF (2020) Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib. JAAD Case Rep Sep 6(9):939–941. https://doi.org/10.1016/j.jdcr.2020.07.035
doi: 10.1016/j.jdcr.2020.07.035
Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol Oct 148(4):927–940. https://doi.org/10.1016/j.jaci.2021.08.009
doi: 10.1016/j.jaci.2021.08.009
Cinats A, Heck E, Robertson L (2018) Janus kinase inhibitors: a review of their emerging applications in Dermatology. Skin Therapy Lett May 23(3):5–9
Dos Santos MR, Ianhez M, Ribeiro BN, de Queiroz BB, Miot HA (2023) Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol Nov 62(11):e595–e598. https://doi.org/10.1111/ijd.16791
doi: 10.1111/ijd.16791
George C, Deroide F, Rustin M (May 2019) Pyoderma gangrenosum - a guide to diagnosis and management Clin Med (Lond). 19(3):224–228. https://doi.org/10.7861/clinmedicine.19-3-224
Gregory MH, Ciorba MA, Deepak P, Christophi GP (2019) Successful treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. Inflamm Bowel Dis Jun 18(7):e87–e88. https://doi.org/10.1093/ibd/izz015
doi: 10.1093/ibd/izz015
Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH (2019) Tofacitinib for the treatment of Pyoderma Gangrenosum. Clin Gastroenterol Hepatol Apr 17(5):991–993. https://doi.org/10.1016/j.cgh.2018.10.047
doi: 10.1016/j.cgh.2018.10.047
Maverakis E, Marzano AV, Le ST et al (2020) Pyoderma Gangrenosum. Nat Rev Dis Primers Oct 8(1):81. https://doi.org/10.1038/s41572-020-0213-x
doi: 10.1038/s41572-020-0213-x
McInnes IB, Byers NL, Higgs RE et al (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther Aug 2(1):183. https://doi.org/10.1186/s13075-019-1964-1
doi: 10.1186/s13075-019-1964-1
Nasifoglu S, Heinrich B, Welzel J (2018) Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol Aug 179(2):504–505. https://doi.org/10.1111/bjd.16468
doi: 10.1111/bjd.16468
Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR (2021) Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol Aug 46(6):1082–1085. https://doi.org/10.1111/ced.14683
doi: 10.1111/ced.14683
Salmón Olavarría P, Rubio Iturria S, Nantes Castillejo Ó (2021) Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig Oct 113(10):733–734. https://doi.org/10.17235/reed.2021.7977/2021
doi: 10.17235/reed.2021.7977/2021
Sasor SE, Soleimani T, Chu MW, Cook JA, Nicksic PJ, Tholpady SS (2018) Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care. Jan 1. ;27(Sup1):S4-s8. https://doi.org/10.12968/jowc.2018.27.Sup1.S4
Scheinberg M, Machado LA, LG MC, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099. https://doi.org/10.1016/j.jtauto.2021.100099
doi: 10.1016/j.jtauto.2021.100099
pubmed: 33997753
pmcid: 8100614
Sedano R, Jairath V (2021) Tofacitinib for the treatment of three Immune-mediated conditions in one patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. Inflamm Bowel Dis Apr 15(5):e65. https://doi.org/10.1093/ibd/izab005
doi: 10.1093/ibd/izab005
Shanmugam VK, McNish S, Shara N et al (2013) Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)). J Foot Ankle Surg. Nov-Dec 52(6):781–785. https://doi.org/10.1053/j.jfas.2013.07.003
doi: 10.1053/j.jfas.2013.07.003
Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM (2022) A comprehensive overview of globally approved JAK inhibitors. Pharm May 6(5). https://doi.org/10.3390/pharmaceutics14051001
Teagle A, Hargest R (2014) Management of pyoderma gangrenosum. J R Soc Med Jun 107(6):228–236. https://doi.org/10.1177/0141076814534407
doi: 10.1177/0141076814534407
Wollina U (2007) Pyoderma gangrenosum–a review. Orphanet J Rare Dis Apr 15:2:19. https://doi.org/10.1186/1750-1172-2-19
doi: 10.1186/1750-1172-2-19